Eventide Asset Management LLC Buys 64,985 Shares of Evolent Health, Inc. (NYSE:EVH)

Eventide Asset Management LLC lifted its stake in shares of Evolent Health, Inc. (NYSE:EVH) by 1.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,804,104 shares of the technology company’s stock after acquiring an additional 64,985 shares during the quarter. Evolent Health makes up approximately 1.9% of Eventide Asset Management LLC’s holdings, making the stock its 11th biggest holding. Eventide Asset Management LLC’s holdings in Evolent Health were worth $107,580,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. increased its holdings in Evolent Health by 3.2% during the 2nd quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company’s stock worth $298,000 after purchasing an additional 480 shares during the period. SeaCrest Wealth Management LLC increased its stake in shares of Evolent Health by 6.3% during the second quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company’s stock valued at $195,000 after buying an additional 600 shares during the period. Arizona State Retirement System raised its holdings in shares of Evolent Health by 2.3% in the second quarter. Arizona State Retirement System now owns 29,083 shares of the technology company’s stock valued at $556,000 after acquiring an additional 649 shares in the last quarter. Covestor Ltd lifted its stake in Evolent Health by 138.1% in the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after acquiring an additional 826 shares during the period. Finally, GAMMA Investing LLC grew its holdings in Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after acquiring an additional 1,556 shares in the last quarter.

Analyst Upgrades and Downgrades

EVH has been the subject of several research reports. Barclays lowered their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. JMP Securities lowered their target price on Evolent Health from $34.00 to $31.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. JPMorgan Chase & Co. cut their price target on Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and set a $20.00 price objective on shares of Evolent Health in a research note on Tuesday, November 12th. Finally, Oppenheimer dropped their price objective on Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $25.90.

Evolent Health Trading Down 2.5 %

Shares of NYSE:EVH opened at $12.93 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a market capitalization of $1.51 billion, a P/E ratio of -14.21 and a beta of 1.58. The business’s 50-day moving average is $21.83 and its 200 day moving average is $23.41. Evolent Health, Inc. has a 1 year low of $11.17 and a 1 year high of $35.00.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.